Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases

BACKGROUND AND AIMS: Despite proven clinical efficacy of vedolizumab (VDZ) for inducing and maintaining remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC), subgroups of patients have no therapeutic benefit from anti-α4β7 integrin therapy with VDZ. Within this study, we aimed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Immunol
Autori principali: Rath, Timo, Billmeier, Ulrike, Ferrazzi, Fulvia, Vieth, Michael, Ekici, Arif, Neurath, Markus F., Atreya, Raja
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2018
Soggetti:
Immunology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6090141/
https://ncbi.nlm.nih.gov/pubmed/30131801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01700
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi